US 11,787,854 B2
Immunological targeting of pathological tau proteins
Einar M. Sigurdsson, Scarsdale, NY (US)
Assigned to NEW YORK UNIVERSITY, New York, NY (US)
Filed by New York University, New York, NY (US)
Filed on Nov. 5, 2020, as Appl. No. 17/90,359.
Application 14/261,506 is a division of application No. 12/813,297, filed on Jun. 10, 2010, granted, now 8,748,386, issued on Jun. 10, 2014.
Application 17/090,359 is a continuation of application No. 15/400,533, filed on Jan. 6, 2017, abandoned.
Application 15/400,533 is a continuation of application No. 14/261,506, filed on Apr. 25, 2014, abandoned.
Claims priority of provisional application 61/185,895, filed on Jun. 10, 2009.
Prior Publication US 2021/0061894 A1, Mar. 4, 2021
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01); G01N 33/68 (2006.01); A61K 39/395 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 39/0005 (2013.01); A61K 39/0007 (2013.01); A61K 39/3955 (2013.01); G01N 33/6896 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/20 (2013.01); C07K 2317/76 (2013.01); G01N 2800/2821 (2013.01)] 13 Claims
 
1. A method of treating Alzheimer's disease or other tauopathy in a subject, or of reducing the severity of Alzheimer's disease or said other tauopathy in said subject, said method comprising:
administering to said subject an immunogen consisting essentially of an immunogenic tau peptide (I), optionally linked to an immunogenic carrier protein directly, or via a linker peptide, wherein:
the amino acid sequence of said immunogenic tau peptide (I) consists of the amino acid sequence of:
 
 (a)
 
 SEQ ID NO: 3
 
 IGS*TE (Tau260-264 P-Ser262);
 
 
 
 (b)
 
 SEQ ID NO: 32
 
 IGXTE (Tau260-264 Pseudo P-Ser262);
 
 
 
 (c)
 
 SEQ ID NO: 12
 
 IGS*TENLKHQPG (Tau260-271 P-Ser262);
 
 
 
 (d)
 
 SEQ ID NO: 41
 
 IGXTENLKHQPG (Tau260-271 Pseudo P-Ser262);
 
 
 
 (e)
 
 SEQ ID NO: 20
 
 VKS*KIGS*TE (Tau256-264 P-Ser262);
 
 or
 
 
 
 (f)
 
 SEQ ID NO: 49
 
 VKXKIGXTE (Tau256-264 Pseudo P-Ser262);
wherein:
S* and P-Ser denote a phospho-serine residue, and X and Pseudo P-Ser denote a glutamic acid or aspartic acid residue;
(II) said optionally linked immunogenic carrier protein is a tetanus toxoid, a Hepatitis B surface antigen, a cholera toxin B, a diphtheria toxoid, a measles virus F protein, a Chlamydia trachomatis major outer membrane protein, a Plasmodium falciparum circumsporozite protein, a Plasmodium falciparum CS antigen, a Schistosoma mansoni triose phosphate isomerase, an Escherichia coli TraT protein, an Influenza virus hemagglutinin, or a keyhole limpet hemocyanine; and
(III) said linker peptide is GPSL (SEQ ID NO: 78), GSG, GSGS (SEQ ID NO: 79), GSGSG (SEQ ID NO: 80), or GSNG);
wherein:
said immunogenic tau peptide (I) peptide is administered in an amount sufficient to elicit an active immune response in said subject to said immunogenic tau peptide; and
said elicited active immune response provides said subject with treatment of Alzheimer's disease or said other tauopathy or reduces the severity of Alzheimer's disease or said other tauopathy in said subject.